Meda acquires product portfolio from Roche

Meda acquires product portfolio from Roche

• Meda acquires world-wide rights to four well-established pharmaceutical 
products
  from Roche
• Meda's position in key therapy areas strengthened
• Sales level of about 500 MSEK
• Purchase price 120 MEUR, equivalent to about 2 times sales

Meda has reached an agreement with the Swiss pharma company Roche to acquire
four of their well-established pharmaceutical products. The acquired products
have strong brand names and the total sales level is 500 MSEK. No employees will
transfer from Roche to Meda in conjunction with the acquisition. Meda acquires
world-wide rights to the products and the most important markets are Germany,
Spain, Switzerland, USA and France. Meda strengthens its position in key therapy
areas; Cardiology, CNS and Pain/Inflammation.

The purchase price is 120 MEUR (approx. 1 125 MSEK), equivalent to about 2 times
sales. The acquisition is dependent on antitrust approval.

“I'm glad that we could reach this deal with Roche. The products strengthen our
marketing affiliates' position in key therapy areas. Therefore, good market
synergies are expected”, said Anders Lonner, CEO Meda.

The four acquired Roche products are;

Active substance/Medical use/Therapy area

Marcoumar/Phenprocoumon/Anticoagulant/Cardiovascular
Torem/Torasemide/Loop diuretic/Cardiovascular
Tilcotil/Tenoxicam/Rheumatoid and osteoarthritis/Pain/Inflammation
Aurorix/Moclobemide/Antidepressant/Central nervous system (CNS)

Marcoumar (phenprocoumon) is a well-established anticoagulant. This product fits
perfectly into Meda's cardiovascular product portfolio. The largest market is
Germany and the total sales level is 200 MSEK.

Torem (torasemide) is a loop diuretic. It is also marketed using trademarks such
as Demadex,Dilutol and Toradiur in more than 30 countries - also in the USA and
in Japan. The product fits well in Meda's antihypertensive product range. The
sales level is about 180 MSEK.

Tilcotil (tenoxicam) is a NSAID drug for the treatment of painful inflammatory
and degenerative disorders of the musculoskeletal system such as rheumatoid and
osteoarthritis, and arthrosis. The product is also marketed using the trademarks
Mobiflex, Tilatil, Tilcitin and Alganex. Tilcotil fits perfectly into Meda's
therapy area Pain / Inflammation. The sales level is approximately 70 MSEK.

Aurorix (moclobemide) is a MAO-A inhibitor and a well-known antidepressant for
specialists to prescribe. Aurorix shows stable market share and a strong patient
binding as it is the original brand. The sales level is approximately 50 MSEK.

For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 8 630 19 62, +46
709 458 878
email: anders.larnholt@meda.se

MEDA AB (publ) is an international specialty pharma company that concentrates on
marketing and market-adapted product development. Acquisitions and long-term
partnerships are fundamental factors that drive the company's strategy. Meda is
represented with own organisations in 26 countries and with more than 1 500
employees within marketing and sales. Meda's products are sold in approximately
120 countries world-wide. The Meda share is listed under Large Cap on the OMX
Nordic Stock Exchange. Find out more, visit www.meda.se.